A Phase II Study of Amplimexon (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults.

Trial Profile

A Phase II Study of Amplimexon (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Imexon (Primary)
  • Indications Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jul 2014 Status changed from active, no longer recruiting to completed according to results published in the Blood.
    • 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 18 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top